EIM
ADMA icon

Essex Investment Management’s ADMA Biologics ADMA Stock Holding History

Essex Investment Management’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-627,931
Closed -$1.22M – 445
2020
Q4 		$1.22M Buy
627,931
+151,218
+32% +$318K 0.15% 210
2020
Q3 		$1.14M Buy
476,713
+15,708
+3% +$43.1K 0.16% 194
2020
Q2 		$1.35M Buy
+461,005
New +$1.32M 0.22% 151

Other funds holding ADMA

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
MS
Maven Securities St Helier, Jersey $5.2B AUM 44.01% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Essex Investment Management's ADMA Position: Q1 2021 in Review

Essex Investment Management sold out of ADMA Biologics (ADMA) in Q1 2021, closing a stake of 627,931 shares — an estimated $1.22M sold.

Essex Investment Management first reported a position in ADMA in Q2 2020 and held it in 3 quarters. The position peaked at $1.35M in Q2 2020. 105 funds tracked by Wall St. Rank hold ADMA as of Q1 2021.

  • Essex Investment Management reported no remaining ADMA Biologics position as of Q1 2021 after selling out during the quarter.
  • Essex Investment Management sold 627,931 ADMA Biologics shares in Q1 2021, an estimated $1.22M.
  • Essex Investment Management first reported a position in ADMA Biologics in Q2 2020 and held it in 3 quarters.
  • Essex Investment Management's ADMA Biologics position peaked at $1.35M in Q2 2020.
  • 105 funds tracked by Wall St. Rank held ADMA Biologics as of Q1 2021.

Based on Essex Investment Management's 13F filing for Q1 2021, filed 12 May 2021.